May 18, 2016, Vancouver, B.C – BGI, headquartered in China, and the Vancouver Prostate Centre (VPC) signed a memorandum of understanding to bring together advanced and cost effective sequencing, genomics and computing technologies of BGI with the world class translational cancer research and drug development program at the VPC.
New tools developed at the Vancouver Prostate Centre (VPC) are substantially advancing the possibility of offering precise, personalized therapies to effectively treat treatment-resistant prostate cancer, also known as metastatic castration-resistant prostate cancer (mCRPC).
The groundbreaking personalized oncology publication led by Drs. Wang and Collins, High fidelity patient- derived xenografts for accelerating prostate cancer discovery and drug development, is one of AACR's most-cited articles from 2014. This Cancer Research publication was posed in this website's News section on January 27, 2014 .
The Networks of Centres of Excellence (NCE) of Canada published an impact story about the recent licensing agreement between Roche and UBC. It describes PC-TRiADD's role in assisting the transition from discovery to intellectual property (IP) to commercialization.
Click here to read the article at the NCE's website.
Congratulations to Dr. Peter Black on winning the European Association of Urology's Best Paper on Clinical Research Award 2016. This prize is awarded annually to to the best paper on a urology topic, and will be presented at the 31st Annual EAU Congress.
The award-winning publication "Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer" is available online at the Journal of the National Cancer Institute.
A potential treatment for advanced prostate cancer developed by University of British Columbia (UBC) and Vancouver Coastal Health Research Institute (VCHRI) scientists has been licensed to pharmaceutical company Roche, marking UBC’s largest licensing agreement to date.
TORONTO (DECEMBER 3, 2015) – Bladder Cancer Canada (BCC) has awarded its inaugural $50,000 Bladder Cancer Canada Research Grant to Dr. Alan So along with Co‐Investigator Dr. Claudia Chavez‐Munoz. They will be studying 3D Bioprinted Tissues: Building a novel platform for bladder cancer.
Bioprinting has the potential to revolutionise medical research well beyond what seemed possible even 20 years ago.
Scientists at the University of British Columbia, Vancouver Coastal Health and the BC Cancer Agency have discovered a protein from malaria that could one day help stop cancer in its tracks.
This new approach, which halted the growth of various tumours in mice, was based on a discovery by collaborators at the University of Copenhagen. While exploring why pregnant women are particularly susceptible to malaria, they found that the mosquito-borne parasite produces a protein that binds to a particular type of sugar molecule in the placenta.
Drs. Akamatsu, Wyatt, Gleave and Collins and their team at the VPC have published the result of their ground-breaking work identifying a gene called PEG10 as a novel and highly-specific therapeutic target for neuroendocrine prostate cancer (NEPC) ("The placental gene PEG10 promotes progression of neuroendocrine prostate cancer", Cell Reports, published online).
The Mr. Lube Tournament for Life 2015 golf fundraiser was held on June 15. The event raised $554,000 which is the largest amount raised in the tournament's 19 year history. The UBC and VGH Hospital Foundation and the Vancovuer Prostate Centre would like to thank the generous donors, volunteers and sponsors who made this event so successful.
You can read more about the event and watch a 4.5 minute video of one man's storyhere.